Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6811 to 6825 of 7707 results

  1. Heart failure (acute decompensated) - nesiritide [ID384]

    Discontinued [GID-TAG376]

    Technology appraisal guidance
    Discontinued

  2. Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]

    Discontinued [GID-TA10722]

    Technology appraisal guidance
    Discontinued

  3. Rolofylline for the treatment of acute heart failure [ID96]

    Discontinued [GID-TA11258]

    Technology appraisal guidance
    Discontinued

  4. Clostridium difficile associated diarrhoea - tolevamer [ID378]

    Discontinued [GID-TAG389]

    Technology appraisal guidance
    Discontinued

  5. Nintedanib for previously treated metastatic colorectal cancer [ID1030]

    Discontinued [GID-TA10138]

    Technology appraisal guidance
    Discontinued

  6. Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]

    In development [GID-TA10882] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]

    In development [GID-TA11272] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Conjunctivitis: antimicrobial prescribing

    Discontinued [GID-NG10166]

    Antimicrobial prescribing guideline
    Discontinued

  9. Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]

    Discontinued [GID-TA10591]

    Technology appraisal guidance
    Discontinued

  10. Pevonedistat with azacitidine for untreated myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia [ID3877]

    Discontinued [GID-TA10767]

    Technology appraisal guidance
    Discontinued

  11. Lymphoma (diffuse large B-cell, untreated) – liposomal vincristine [ID1123]

    Discontinued [GID-TA11208]

    Technology appraisal guidance
    Discontinued

  12. Melanoma (advanced, unresectable, metastatic, NRAS mutation positive) - binimetinib [ID833]

    Discontinued [GID-TA10074]

    Technology appraisal guidance
    Discontinued

  13. Prostate cancer (hormone relapsed, metastatic) - rilimogene galvacirepvec (with rilimogene glafolivec, chemotherapy-naive) [ID1018]

    Discontinued [GID-TA11177]

    Technology appraisal guidance
    Discontinued

  14. Breast cancer (HER2-negative, BRCA-mutation, unresectable) - niraparib [ID1084]

    Discontinued [GID-TA11178]

    Technology appraisal guidance
    Discontinued

  15. Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289

    Discontinued [GID-TA10210]

    Technology appraisal guidance
    Discontinued